📢 LabGenomics Establishes a Comprehensive NGS Portfolio for Cancer Reimbursement Testing, Targeting the U.S. Market LabGenomics has built a complete portfolio of next-generation sequencing (NGS) products for all selective reimbursement tests related to solid tumors and hematologic cancers. The company's NGS portfolio includes △ OTD Lung, a level 1 companion diagnostic service for non-small cell lung cancer, △ level 2 analysis service for all types of solid tumors, △ OTD Liquid, a liquid biopsy service for solid tumors, and △ HemaScan, a comprehensive analysis service for hematologic cancers. ✅ These achievements stem from the company's sustainable growth strategies, including 'Open R&D' and 'Open Innovation.' In particular, OTD Lung is praised for transforming lung cancer treatment paradigms by enabling the detection of various genetic mutations from a small sample and quickly selecting drugs within 10 days. A representative from LabGenomics' Hospital Solutions Team stated, "Unlike traditional companion diagnostic methods such as fluorescence in situ hybridization (FISH) or real-time PCR, OTD Lung can detect multiple genetic mutations in a single test, allowing for precise drug prescription. Additionally, the NGS panel-based selective reimbursement test for non-small cell lung cancer adenocarcinoma is offered at a price up to 61% lower than other cancer types, making it more affordable and driving rapid revenue growth." Since the service launch last year, the OTD Lung test results over the past year until August have shown a positive rate of 49% for drug-eligible cases, which is 2-3 times higher than the positive rates achieved with conventional real-time PCR, offering more patients treatment opportunities. ✅ The company plans to continue expanding cancer diagnostics and introduce these services to U.S. CLIA-certified labs, with the goal of boosting both scale and profitability. LabGenomics' CEO, Kim Jung-joo, emphasized, "All of our employees are committed to providing fast and accurate analysis results to give even one more cancer patient a chance for treatment. Leveraging our cancer diagnostics expertise and references accumulated over the past eight years, we will expand the 'K-Cancer Diagnosis' service into U.S. CLIA labs." 🔗 https://lnkd.in/dPkKVfpD #LabGenomics #NGS #CLIALab #OTDLung
LabGenomics 랩지노믹스’s Post
More Relevant Posts
-
Recruiters must be very keen to employ healthcare workers with the knowledge acquired in the medical curriculum. Medication are no longer healing patients and the knowledge acquired in the classroom, are medically undermined. Research to improve quality of health services are on going. External intervention like medicine is fading away. Gene therapy is taking over medication treatment methods. We have designed a therapy services called the right hand side of patients, the blood purifying therapy and psychological assessment. Blood has natural healing capabilities, but gene expression or gene editing does not address underlying cause of patients healing needs. Patients state of health are associated with thick blood, dark in color and circulatory systems partially blocked. As a result, patients are at risk as we are waiting for the implementation of gene therapy and blood purifying therapy.
To view or add a comment, sign in
-
Seeing the World in a New Light: The Dawn of Gene Therapy for Sensory Loss Have you ever wondered what it's like to experience the world without one of your senses? Imagine the silence of a world without music or the darkness of a world without light. This was the reality for many born with inherited forms of blindness and deafness—until now. Recent breakthroughs in gene therapy trials have ushered in a new era of hope. For the first time, scientists have restored vision and hearing in individuals with congenital conditions. This isn't just a medical triumph; it's a gateway to a fuller life for those affected. The importance of this research cannot be overstated. It addresses a profound human problem: the isolation and challenges faced by those living with sensory impairments. The therapies developed target the very root of these conditions, offering not just treatment, but a potential cure. For instance, an 18-month-old toddler, born deaf, can now hear thanks to a gene therapy trial that took a mere 16 minutes. This procedure involved a harmless virus delivering a working copy of a crucial gene directly into the cochlea, restoring auditory function. Similarly, another trial used CRISPR gene editing to improve vision in individuals with a rare form of inherited blindness. These are not just medical milestones; they are life-changing interventions. But what more can be done? The success of these trials is just the beginning. The next steps involve refining these therapies, making them accessible to more people, and ensuring long-term efficacy. Continued research and funding are essential to bring these treatments from the lab to the lives of millions worldwide. This research is a testament to human ingenuity and compassion. It's a reminder that science, at its best, serves to improve the human condition. #GeneTherapy #Breakthrough #SensoryRestoration #CRISPR #Innovation #Healthcare #MedicalScience #LifeChanging #Accessibility #Research #Hope
To view or add a comment, sign in
-
Regulation of gene expression is one molecular mechanism that would be expected to lead to relatively stable changes within neurons. According to this scheme, repeated exposure to a drug of abuse or stress, by causing repeated perturbation of intracellular signal transduction pathways, would lead eventually to changes in nuclear function and to altered rates of transcription of particular target genes. #UnitedSeniorAssociation #Healthcare #NIH #HHSOIG #AssistedLiving #MemoryCare #USA #KloeKorby #Hospitals #ADA #HSS #Technology #CMS #Neuroscience #OIG #Dementia #VA #Alzheimers #Diabetes #ACL #HIPPA #SeniorLiving #WearableDevices #AMA #Nutrition #Covid19 #Telehealth #ACF #Cybersecurity #MobileHealth #DigitalHealth #HealthInsurance #SeniorCare #Medicare #HealthCareInnovation #HealthEquity #FDA #ValueBasedCare #WearableTech #Eldercare #PatientCare #NursingHomes #MentalHealth #PreventativeCare #HomeHealthcare #CDC
To view or add a comment, sign in
-
Gene Therapy: A Future Without Hearing Aids or Cochlear Implants? What if hearing loss could be reversed instead of managed? Gene therapy is no longer just a theoretical concept—clinical trials are underway, showing promising results. Here’s how gene therapy is transforming the game: • Fixing the Root Cause: Instead of amplifying sound or bypassing damaged auditory pathways ,gene therapy repairs damaged genes responsible for hearing loss. • Treating genetic hearing loss : 50% of genetic hearing loss are linked to genetic mutations, Gene therapy can potentially reverse inherited hearing loss. • One-Time Treatment: Unlike devices requiring maintenance, this could be a lasting, one-time solution. Though still in development, gene therapy is an exciting step toward curing hearing loss rather than managing it. P.S. it is not yet FDA-approved and is not currently available as a treatment option. What would the role of audiologists look like if gene therapy becomes a reality?
To view or add a comment, sign in
-
-
Promising Gene Therapy for Hereditary Deafness! Exciting developments from the field of genetic hearing therapies. Researchers have achieved promising preliminary results using gene therapy to treat a rare form of congenital deafness caused by mutations in the OTOF gene. In a groundbreaking clinical trial, five deaf children born with mutations in the OTOF gene received injections of a corrective gene directly into both cochleae (inner ears). All five showed substantial hearing improvements and recovery of speech perception abilities just months after the one-time gene therapy! What makes this even more remarkable - the children went from profound deafness to mild-moderate hearing levels. Some could even localize sound sources, which requires input from both ears. The novel gene therapy was found to be relatively safe, with no serious adverse events reported in the initial 6-month follow-up period after treatment. While still an early-stage study, these findings provide encouragement that gene therapy could potentially restore hearing in individuals born deaf due to OTOF mutations. Further research with larger patient groups is needed to validate the safety and efficacy of this approach. But it represents a pioneering step towards making hereditary deafness a treatable condition. #GeneTherapy #Deafness
To view or add a comment, sign in
-
-
🔬 Exciting Breakthrough in Personalized Medicine! 🔬 Researchers have achieved a remarkable milestone in the treatment of profound genetic deafness through gene therapy, with significant improvements observed within just 24 weeks. This success not only underscores the potential of gene therapy as a transformative approach to combating genetic disorders but also marks a pivotal moment in personalized medicine. 👉 Read the full details of this groundbreaking development here: https://lnkd.in/e_vQn-MK Are you interested in learning more about how gene therapy can treat diseases by targeting individual genetic profiles? Would you like to delve deeper into the science and possibilities of gene therapy in personalized medicine? 👇 Comment if you are interested in learning more about gene therapy 👇 Let us know if you wish to write about gene therapy and be a content creator
To view or add a comment, sign in
-
Lovely story here - another gene therapy success, this one giving a young girl her hearing back. 🧬 In addition to the gene sequencing and targeting platforms involved in developing such a medicine, delivery of the gene to the correct cells is also vital. 🧿 In this case, a ~25 nm AAV vector was used to deliver the therapeutic DNA successfully. For more info on gene therapy and its vectors, see here: https://lnkd.in/d5GPasft #AAV #GeneTherapy #DrugDelivery #DrugTargeting #Regeneron
18-month-old girl, Opal Sandy, born deaf, received a groundbreaking gene therapy earlier this year developed by Regeneron Pharmaceuticals. Today, she can hear soft sounds like whispers and is even starting to speak her first words, like "Dada", a transformation that has brought immeasurable joy to her parents, Jo and James. 👉 The therapy targets the OTOF gene mutation causing Opal’s deafness, replacing faulty DNA with a working copy and restoring her hearing. After just six months, Opal’s hearing has improved to nearly normal levels. ➡️ Opal’s story highlights how gene therapy is not just a temporary fix but a long-term answer for children with genetic hearing loss. This breakthrough offers hope to millions of families who once thought such a change was impossible. This is not just a small breakthrough, it’s the start of a permanent solution in treating genetic conditions, correcting the root causes of diseases, and changing lives for good. Nice to see the wide application of gene therapies curing patients! #genetherapy #cellandgenetherapy #biotech #CGTweekly
To view or add a comment, sign in
-
-
Thoughts on this? >> Chinese gene therapy restores hearing in deaf children in trial - Ynetnews >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #healthcare #pharma #competitivemarketing #pharmaceutical
To view or add a comment, sign in
-
18-month-old girl, Opal Sandy, born deaf, received a groundbreaking gene therapy earlier this year developed by Regeneron Pharmaceuticals. Today, she can hear soft sounds like whispers and is even starting to speak her first words, like "Dada", a transformation that has brought immeasurable joy to her parents, Jo and James. 👉 The therapy targets the OTOF gene mutation causing Opal’s deafness, replacing faulty DNA with a working copy and restoring her hearing. After just six months, Opal’s hearing has improved to nearly normal levels. ➡️ Opal’s story highlights how gene therapy is not just a temporary fix but a long-term answer for children with genetic hearing loss. This breakthrough offers hope to millions of families who once thought such a change was impossible. This is not just a small breakthrough, it’s the start of a permanent solution in treating genetic conditions, correcting the root causes of diseases, and changing lives for good. Nice to see the wide application of gene therapies curing patients! #genetherapy #cellandgenetherapy #biotech #CGTweekly
To view or add a comment, sign in
-
-
Gene therapy will be the future 🧬🔬🥼
18-month-old girl, Opal Sandy, born deaf, received a groundbreaking gene therapy earlier this year developed by Regeneron Pharmaceuticals. Today, she can hear soft sounds like whispers and is even starting to speak her first words, like "Dada", a transformation that has brought immeasurable joy to her parents, Jo and James. 👉 The therapy targets the OTOF gene mutation causing Opal’s deafness, replacing faulty DNA with a working copy and restoring her hearing. After just six months, Opal’s hearing has improved to nearly normal levels. ➡️ Opal’s story highlights how gene therapy is not just a temporary fix but a long-term answer for children with genetic hearing loss. This breakthrough offers hope to millions of families who once thought such a change was impossible. This is not just a small breakthrough, it’s the start of a permanent solution in treating genetic conditions, correcting the root causes of diseases, and changing lives for good. Nice to see the wide application of gene therapies curing patients! #genetherapy #cellandgenetherapy #biotech #CGTweekly
To view or add a comment, sign in
-